Clinical Trial Update: Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy [Phase 2]

View source ↗

Summary

Phase 2 trial update on efficacy and safety of multiple Viaskin Peanut doses in adults and children with peanut allergy; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 2 | Status: COMPLETED | Results posted: 2021-10-27